The role of phototherapy in cutaneous T-cell lymphoma

Journal of Drugs in Dermatology

Volumn 9, Issue 7, 2010, Pages 764-772

  Pothiawala, Salma Z ^a   Baldwin, Brooke T ^a   Cherpelis, Basil S ^a   Lien, Mary H ^a   Fenske, Neil Alan ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIBIOTIC AGENT; BEXAROTENE; DIURETIC AGENT; DNA; ETRETIN; ISOTRETINOIN; PSORALEN; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; BROADBAND ULTRAVIOLET B; CANCER ADJUVANT THERAPY; CANCER RISK; CANCER STAGING; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ASSESSMENT; CUTANEOUS T CELL LYMPHOMA; DNA CROSS LINKING; DNA DAMAGE; DRUG EFFICACY; DRUG METABOLISM; DRUG RECEPTOR BINDING; ERYTHEMA; EXTRACORPOREAL PHOTOPHERESIS; FOLLOW UP; GENE EXPRESSION; HUMAN; HYPERPIGMENTATION; INGESTION; KERATINOCYTE; LIVER FUNCTION; LOW DRUG DOSE; MAINTENANCE THERAPY; MITOSIS; MONOTHERAPY; MYCOSIS; NARROWBAND ULTRAVIOLET B; NAUSEA AND VOMITING; NON MELANOMA SKIN CANCER; PATIENT MONITORING; PHOTOAGING; PHOTOCHEMOTHERAPY; PHOTODERMATOSIS; PHOTOSENSITIVITY; PHOTOTHERAPY; PHOTOTOXICITY; PRURITUS; PUVA; RECURRENCE RISK; RELAPSE; REMISSION; REVIEW; RISK ASSESSMENT; SEZARY SYNDROME; SKIN BURNING SENSATION; SKIN CANCER; SKIN CARCINOGENESIS; SKIN CELL; SUNBURN; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; METHODOLOGY; SKIN TUMOR;

HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; PHOTOPHERESIS; PHOTOTHERAPY; PUVA THERAPY; SKIN NEOPLASMS; ULTRAVIOLET THERAPY;

EID: 77955908558     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Murphy GF. Cutaneous T-cell lymphoma. Adv Pathol. 1988;1:131- 156.
2. Bunn PA Jr., Lamberg SI. Report of the committee on staging and classification of cutaneous t-cell lymphomas. Cancer Treat Rep. 1979;63:725-728. (Pubitemid 9217604)
3. Rapini RP, Jorizzo JL, Bolognia JL. Dermatology. 1st ed. St. Louis: Mosby. 2003.
4. Toro JR, Stoll H Jr. Oseroff AR. Prognostic factors and evaluation of mycosis fungoides and Sézary syndrome. J Am Acad Dermatol. 1997;37:58-67. (Pubitemid 27287694)
5. Vonderheid EC, Tan ET, Kantor AF, et al. Long-term efficacy, curative potential and carcinogenicity of topical mechloretamine chemotherapy in cutaneous T-cell lymphoma. J Am Acad Dermatol. 1989;20:416-428. (Pubitemid 19086776)
6. Zackheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides. Arch Dermatol. 1998;134:949-954.
7. Gupta AK, Anderson TF. Psolaren photochemotherapy. J Am Acad Dermatol. 1987;17:703-734.
8. Roenigk HH Jr., Kuzel TM, Skoutelis AP, et al. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. J Invest Dermatol. 1990;95:198S-205S.
9. Quiros PA, Jones GW, Kacinski BM, et al. Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides). Int J Radiol Oncol Biol Phys. 1997;38:1027- 1035.
10. Armus S, Keyes B, Cahill C, et al. Photopheresis in the treatmentof cutaneous T-cell lymphoma. J Am Acad Dermatol. 1990;23:898- 902.
11. Straus DJ, Duvic M, Kuzel T, et al. Results of a phase II 11. trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma. Cancer. 2007;109:1799-1803. (Pubitemid 46668543)
12. O'Brien S, Kurzrock R, Duvie M, et al. 2-Clorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. Blood. 1994;84:733-738. (Pubitemid 24223867)
13. Hesketh P, Caguioa P, Koh H, et al. Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 1993;11:1682-1696.
14. Eklund JW, Kuzel TM. Denileukin diftitox: A concise clinical review. Expert Rev Anticancer Ther. 2005;5(1):33-38. (Pubitemid 40287434)
15. Resnik KS, Vonderheid EC. Home UV phototherapy of early mycosis fungoides: Long-term follow-up observations in thirty-one patients. J Am Acad Dermatol. 1993;29:73-77. (Pubitemid 23197200)
16. Clark C, Dawe RS, Evans AT, et al. Narrow-band TL-01 phototherapy for patch-stage mycosis fungoides. Arch Dermatol. 2000;136:748- 752.
17. Ramsay DL, Lish KM, Yalowitz CB, et al. Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma. Arch Dermatol. 1992;128:931-933.
18. Baron D, Stevens SR. Phototherapy for cutaneous T-cell lymphoma. Dermatol Ther. 2003;16:303-310. (Pubitemid 38044674)
19. Kunisada M, Sakumi K, Tominaga Y, et al. 8-Oxoguaninie formation induced by chronic UVB exposure makes Ogg1 knockout mice susceptible to skin cancer. Cancer Res. 2005;65:6006-6010. (Pubitemid 40994382)
20. Kraemer KH. Sunlight and skin cancer: Another link revealed. Proc Natl Acad Sci USA. 1997;94:11-14. (Pubitemid 27027155)
21. Weischer M, Blum A, Eberhard F, et al. No evidence for increased skin cancer risk in psoriasis patients treated with broadband or narrowband UVB phototherapy: A first retrospective study. Acta Derm Venereol. 2004;84:370-374. (Pubitemid 39312270)
22. Hodge L, Briffa DV, Warin A, et al. Photochemotherapy in mycosis fungoides. Br Med J. 1977;2:1257-1259. (Pubitemid 8215936)
23. Herrmann JJ, Roenigk HH, Hurria A, et al. Treatment of mycosis fungoides with photochemotherapy (PUVA): Long-term follow-up. J Am Acad Dermatol. 1995;33:234-242.
24. Gilchrest BA. Methoxsalen photochemotherapy for mycosis fungoides. Cancer Treat Rep. 1979;63:663-667. (Pubitemid 9217595)
25. Roenigk H. Photochemotherapy for mycosis fungoides. Arch Dermatol. 1977;113: 1047-1051.
26. Molin L, Thomsen K, Volden G, et al. Photochemotherapy (PUVA) in the tumour stage of mycosis fungoides: A report from the Scandinavian Mycosis Fungoides Study Group. Acta Dermatovener. 1981;61:52-54. (Pubitemid 11162867)
27. Lowe N, Cripps D, Dufton P, et al. Photochemotherapy for mycosis fungoides. Arch Dermatol. 1979;115:50-53.
28. Bleehen SS, Vella Briffa D, Warin AP, Photochemotherapy in mycosis fungoides. Clin Exp Dermatol. 1978;3:377-387.
29. Briffa DV, Warin AP, Harrington CI, et al. Photochemotherapy in mycosis fungoides: A study of 73 patients. Lancet. 1980;2:49-53.
30. Honigsmann H, Brenner W, Rauschmeier W, et al. Photochemotherapy for cutaneous T cell lymphoma. J Am Acad Dermatol. 1984;10:238-245.
31. Querfeld C, Rosen ST, Kuzel TM, et al. Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol. 2005;141:305-311. (Pubitemid 40365446)
32. Akaraphanth R, Douglass M, Lim H. Hypopigmented mycosis fungoides: Treatment and 6-1/2-year follow-up of 9 patients. J Am Acad Dermatol. 2000;42:33-39. (Pubitemid 30470317)
33. Stern RS, Bolshakov S, Nataraj AJ, et al. p53 mutation in nonmelanoma skin cancers occurring in psoralen ultraviolet A-treated patients: Evidence for heterogeneity and field cancerization. J Invest Dermatol. 2002;119:522-526. (Pubitemid 35001966)
34. Nijsten TE, Stern RS. The increased risk of skin cancer is persistent after discontinuation of psoralen + ultraviolet A: A cohort study. J Invest Dermatol. 2003;121:252-258. (Pubitemid 36969897)
35. Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA): The PUVA Follow-up Study. N Engl J Med. 1997;336:1041-1045. (Pubitemid 27163855)
36. Stern RS. The risk of melanoma in association with long-term exposure to PUVA: The PUVA Follow up Study. J Am Acad Dermatol. 2001;44:755-761. (Pubitemid 32391161)
37. Hannuksela-Svahn A, Pukkala E, Koulu L, et al. Cancer incidence among Finnish psoriasis patients treated with 8-methoxypsoralen bath PUVA. J Am Acad Dermatol. 1999;40:694-696. (Pubitemid 29230354)
38. Diederen PV, Van Weelden H, Sanders CJ, et al. Narrow-band UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides: A retrospective study. J Am Acad Dermatol. 2003;48:215- 219.
39. Hofer A, Cerroni L, Kerl H, et al. Narrow-band (311-nm) UV-B therapy for small plaque parapsoriasis and early-stage mycosis fungoides. Arch Dermatol. 1999;135:1377-1380.
40. European Organisation for Research and Treatment of Cancer. Protocol 21011. A randomised, open-label phase III trial to evaluate the efficacy and safety of bexarotene (Targretin™) capsules combined with PUVA, compared to PUVA treatment alone in patients with mycosis fungoides. Available at http://www.eortc.be/protoc/details. asp?protocol=21011. Accessed 28 November 2007.
41. Gathers RC, Scherschun L, Malick F, et al. Narrow-band UVB phototherapy for early-stage mycosis fungoides. J Am Acad Dermatol. 2002;47:191-197.
42. Gökdemir G, Barutcuoglu B, Sakiz D, et al. Narrow-band UVB phototherapy for early-stage mycosis fungoides: Evaluation of clinical and histopathological changes. JEADV. 2006;20:804-809. (Pubitemid 44102913)
43. Man I, Crombie IK, Dawe RS, et al. The photocarcinogenic risk of narrow-band UVB (TL-01) phototherapy: early follow-up data. Br J Dermatol. 2005;152:755-757. (Pubitemid 40571310)
44. Gambichler T, Breuckmann F, Boms S, et al. Narrow-band UVB phototherapy in skin conditions beyond psoriasis. J Am Acad Dermatol. 2005;52:660-670. (Pubitemid 40585439)
45. Ozawa M, Ferenczi K, Kikuchi T, et al. 312-nanometer ultraviolet Blight (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions. J Exp Med.1999;189:711-718. (Pubitemid 29193372)
46. Boztepe G, Sahin S, Ayhan M, et al. Narrow-band ultraviolet B phototherapy to clear and maintain clearance in patients with mycosis fungoides. J Am Acad Dermatol. 2005;53:242-246. (Pubitemid 40979579)
47. Ghodsi SZ, Hallaji Z, Balighi K, et al. Narrow-band UVB in the treatment of early stage mycosis fungoides: Report of 16 patients. Clin Exp Dermatol. 2005;30:376-378. (Pubitemid 40835334)
48. Brazzelli V, Antoninetti M, Palazzini S, et al. Narrow-band ultraviolet therapy in early-stage mycosis fungoides: Study on 20 patients. Photodermatol Photoimmunol Photomed. 2007;23:229-233. (Pubitemid 350055610)
49. Pavlotsky F, Barzilai A, Kasem R, et al. UVB in the management of early stage mycosis fungoides, J Eur Acad Dermatol Venereol. 2006;20:565-572.
50. Ahmad K, Rogers S, McNicholas PD, et al. Narrowband UVB and PUVA in the treatment of mycosis fungoides: A retrospective study. Acta Derm Venereol. 2007;7:413-417. (Pubitemid 351373419)
51. El-Mofty M, El-Darouty M, Salonas M, et al. Narrow band UVB (311 nm), psoralen UVB (311 nm) and PUVA therapy in the treatment of early-stage mycosis fungoides: A right-left comparative study. Photodermatol Photoimmunol Photomed. 2005;21:281-286. (Pubitemid 43009278)
52. Gibbs NK, Traynor NJ, MacKie RM, et al. The phototumorigenic potential of broad-band (270-350 nm) and narrowband (311-313 nm) phototherapy sources cannot be predicted by their edematogenic potential in hairless mice skin. J Invest Dermatol. 1995;104:359- 363.
53. Wulf HC, Hansen AB, Bech-Thomsen N. Differences in narrow-band ultraviolet B and broad-spectrum ultraviolet photocarcinogenesis in lightly pigmented hairless mice. Photodermatol Photoimmumol Photomed. 1994;10:192-197. (Pubitemid 24357434)
54. Flindt-Hansen H, McFadden N, Eeg-Larsen T, et al. Effect of a new narrow-band UVB lamp on photocarcinogenesis in mice. Acta Dermatol Venereol. 1991;71:245-248.
55. Kunisada M, Kumimoto H, Ishizaki K, et al. Narrow-band UVB induces more carcinogenic skin tumors than broadband UVB through the formation of cyclobutane pyrimidine dimer. J Invest Dermatol. 2007;127:2865-2871. (Pubitemid 350134829)
56. Rupoli S, Goteri G, Pulini S, et al. Long-term experience with lowdose interferon-alpha and PUVA in the management of early mycosis fungoides. Eur J Haematol. 2005;75:136-145. (Pubitemid 41008284)
57. Stadler R. Optimal combination with PUVA: Rationale and clinical trial update. Oncology. 2007;21:29-32.
58. Thomsen K, Hammar H, Molin L et al. Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage. A report from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol. 1989;69:536-538. (Pubitemid 20000564)
59. Stadler R, Otte H-G, Luger T, et al. Prospective randomised multicenter clinical trial on the use of interferon α-2a plus acitretin versus interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood. 1998;92:3578-3581. (Pubitemid 28525182)
60. Singh F, Lebwohl MG. Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series. J Am Acad Dermatol. 2004;51:570-573. (Pubitemid 39278076)
61. Zhang C, Hazarika P, Xioa N, et al. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res. 2002;8:1234-1240. (Pubitemid 34517663)
62. Budgin JB, Richardson SK, Newton SB, et al. Biological effects of bexarotene in cutaneous T-cell lymphoma. Arch Dermatol. 2005;141:315-321. (Pubitemid 40365447)
63. Talpur R, Ward S, Apisarnthanarax N, et al. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 2002;47:672-684. (Pubitemid 35239327)
64. Guitart J, Tucker R, Stevens V. Low dose bexarotene (Targretin®) capsules and phototherapy for early stage cutaneous T-cell lymphoma. Proceedings of the 63rd Society for Investigative Dermatology Annual Meeting, Los Angeles, CA. May 15-18 2002; Abstract 199.
65. Edelson R, Berger C, Gasparro F, et al. Treatment of cutaneous Tcell lymphoma by extracorporeal photochemotherapy. preliminary results. N Engl J Med. 1987;316:297-303. (Pubitemid 17036377)
66. Quaglino P, Comessatti A, Ponti R, et al. Reciprocal modulation of circulating CD4+CD25+bright T cells induced by extracorporeal photochemotherapy in cutaneous T-cell lymphoma and chronic graft-versus-host-disease patients. Int J Immunopathol Pharmacol. 2009;22:353-362.
67. Heshmati F. Mechanisms of action of extracorporeal photochemotherapy. Transfus Apher Sci. 2003;29:61-70. (Pubitemid 36873797)
68. Zic JA. The treatment of cutaneous T-cell lymphoma with photopheresis. Dermatol Ther. 2003;16:337-346. (Pubitemid 38044678)
69. McKenna KE, Whittaker S, Rhodes LE, et al. Evidence-based practice of photopheresis 1987-2001: A report of a workshop of the British photodermatology group and the U.K. skin lymphoma group. Br J Dermatol. 2006;154:7-20. (Pubitemid 43381314)
70. Girardi M, Knobler R, Edelson R. Selective immmunotherapy through extracorporeal photochemotherapy: Yesterday, today, and tomorrow. Hematol Oncol Clin North Am. 2003;17:1391-1403. (Pubitemid 37523676)
71. Knobler R, Jantschitsch C. Extracorporeal photochemoimmunotherapy in cutaneous T-cell lymphoma. Transfus Apher Sci. 2003;28:81-89. (Pubitemid 36298594)
72. Lamioni A, Parisi F, Isacchi G, et al. The immunological effects of extracorporeal photopheresis unraveled: Induction of tolerogenic dendritic cells in vitro and regulatory T cells in vivo. Transplantation. 2005;79:846-850. (Pubitemid 40546206)
73. Miracco C, Rubegni P, De Aloe G, et al. Extracorporeal photochemotherapy induces apoptosis of infiltrating lymphoid cells in patients with mycosis fungoides in early stages. A quantitative histological study. Br J Dermatol. 1997;137:549-557. (Pubitemid 27469505)
74. Rook AH, Suchin KR, Kao DM, et al. Photopheresis: Clinical applications and mechanism of action. J Investig Dermatol Symp Proc. 1999;4:85-90. (Pubitemid 29491262)
75. Stevens SR, Baron ED, Masten S, et al. Circulating CD4+CD7- lymphocyte burden and rapidity of response: Predictors of outcome in the treatment of sezary syndrome and erythrodermic mycosis fungoides with extracorporeal photopheresis. Arch Dermatol. 2002;138:1347-1350.
76. Russell-Jones R. Shedding light on photopheresis. Lancet. 2001;357:820-821.
77. Kim EJ, Hess S, Richardson SK, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest. 2005;115:798-812.
78. Scarisbrick JJ, Taylor P, Holtick U, et al. On behalf of the Photopheresis Expert Group. U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease. Br J Dermatol. 2008;158:659-678. (Pubitemid 351415723)
79. Zic JA, Stricklin GP, Greer JP, et al. Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy. J Am Acad Dermatol. 1996;35:935-945. (Pubitemid 26422118)
80. Gollnick HP, Owsianowski M, Ramaker J, et al. Extracorporeal photopheresis-A new approach for the treatment of cutaneous T cell lymphomas Recent Results. Cancer Res. 1995;139:409-415.
81. Heald P, Rook A, Perez M, et al. Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J Am Acad Dermatol. 1992;27:427-433.
82. Armus S, Keyes B, Cahill C, et al. Photopheresis for the treatment of cutaneous T cell lymphoma. J Am Acad Dermatol. 1990;23:898- 902.
83. Gottlieb SL, Wolfe JT, Fox FE, et al. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: A 10-year experience at a single institution. J Am Acad Dermatol. 1996;35:946-957. (Pubitemid 26422119)
84. Miller JD, Kirkland EB, Domingo DS, et al. Review of extracorporeal photopheresis in early-stage (IA, IB, and IIA) cutaneous T-cell lymphoma. Photodermatol Photoimmunol Photomed. 2007;23:163- 171.
85. Demierre MF, Foss FM, Koh HK. Proceedings of the international consensus conference on cutaneous T-cell lymphoma (CTCL) treatment recommendations. Boston, Massachusetts, Oct. 1 and 2, 1994. J Am Acad Dermatol. 1997;36:460-466. (Pubitemid 27131972)
86. Knobler E, Warmuth I, Cocco C, et al. Extracorporeal photochemotherapy - The Columbia presbyterian experience. Photodermatol Photoimmunol Photomed. 2002;18:232-237. (Pubitemid 35331391)
87. Duvic M, Chiao N, Talpur R. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma. J Cutan Med Surg. 2003;7:3-7.
88. Bisaccia E, Gonzalez J, Palangio M, et al. Extracorporeal photochemotherapy alone or with adjuvant therapy in the treatment of cutaneous T-cell lymphoma: A 9-year retrospective study at a single institution. J Am Acad Dermatol. 2000;43:263-271. (Pubitemid 30626004)
89. Duvic M, Hester JP, Lemak NA. Photopheresis therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 1996;35:573-579. (Pubitemid 26427060)
90. Di Renzo M, Rubegni P, De Aloe G, et al. Extracorporeal photochemotherapy restores Th1/Th2 imbalance in patients with early stage cutaneous T-cell lymphoma. Immunology. 1997;92:99-103. (Pubitemid 27380887)
91. Wollina U, Liebold K, Kaatz M, et al. Survival of patients with cutaneous T-cell lymphoma after treatment with extracorporeal photochemotherapy. Oncol Rep. 2000;7:1197-1201.
92. Prinz B, Behrens W, Holzle E, Plewig G. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma - The Dusseldorf and Munich experience. Arch Dermatol Res.1995;287:621-626.
93. Rubegni P, De Aloe G, Fimiani M. Extracorporeal 93. photochemotherapy in long-term treatment of early stage cutaneous T-cell lymphoma. Br J Dermatol. 2000;143:894-896.
94. Konstantinow A, Balda BR. Treatment of cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J Europ Acad Dermatol Vener. 1997;9:111-117. (Pubitemid 27400409)
95. Suchin KR, Cucchiara AJ, Gottleib SL, et al. Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: A 14-year experience at a single institution. Arch Dermatol. 2002;138:1054-1060. (Pubitemid 34875609)
96. Wollina U, Looks A, Meyer J, et al. Treatment of cutaneous T cell lymphoma stage II with interferon-alpha-2a and extracorporeal photochemotherapy: A prospective controlled trial. Ann NY Acad Sci. 2001;941:210-213. (Pubitemid 32928349)